Security
Ensysce Biosciences, Inc. Warrant 06/30/2026 · ENSCW
ENSCWOTCWarrantHistorical · closed Jun 30, 2026CIK 1716947Updated Nov 1, 2026
Name history
Leisure Acquisition Corp. · through Jun 30, 2021
Current security for this SEC filerENSC · NASDAQ
ENSCW price & chart
Historical security
This listing closed Jun 30, 2026. Live provider charts are shown only for current listings.
Current security: ENSC
In the news
No coverage from other publishers is available.
Recent filings
PRE 14A filing
S-3 filing
Financial Statements and Exhibits
Items 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
Other Events
Items 8.01
Show 5 more recent filings
Other Events
Items 8.01
D filing
Items 06b
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 3,179,464Source | 9,384,724Source | 2,957,273Source | 5,574,455Source | 2,795,620Source | 2,167,803Source | 4,611,874Source | 5,074,190Source | 7,452,479Source | 5,597,232Source | 2,708,085Source | 5,885,052Source |
| Property, Plant and Equipment, NetUSD | 123,643Source | — | 111,063Source | — | — | 117,596Source | — | — | 124,129Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,673,218Source | 4,153,592Source | 676,704Source | 2,211,575Source | 1,043,231Source | 745,482Source | 3,052,491Source | 3,404,349Source | 4,310,354Source | 3,502,077Source | 1,123,604Source | 3,147,702Source |
| Assets, CurrentUSD | 2,928,270Source | 9,090,507Source | 2,846,210Source | 5,281,595Source | 2,459,737Source | 2,008,540Source | 4,400,991Source | 4,696,640Source | 7,242,468Source | 5,344,682Source | 2,288,868Source | 5,299,169Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,250,641Source | 3,154,110Source | 1,752,695Source | 1,865,041Source | 1,192,283Source | 1,263,058Source | 1,326,498Source | 1,196,067Source | 2,511,769Source | 1,718,490Source | 1,067,703Source | — |
| Other Assets, NoncurrentUSD | 127,551Source | 294,217Source | — | 292,860Source | 335,883Source | 41,667Source | 210,883Source | 377,550Source | 85,882Source | 252,550Source | 419,217Source | 585,883Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,304,750Source | 2,804,997Source | 4,068,106Source | 2,514,043Source | 1,316,235Source | 2,836,815Source | 1,891,356Source | 1,653,561Source | 4,567,729Source | 2,217,293Source | 3,359,352Source | 9,914,704Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 320Source | 1,387Source | 1,624Source | 241Source | 815Source | 929Source | 165Source | 733Source | 459Source | 136Source | 315Source | 642Source |
| Additional Paid in CapitalUSD | 138,155,394Source | 132,886,700Source | 145,063,802Source | 136,612,043Source | 128,448,699Source | 142,935,443Source | 134,538,708Source | 128,422,232Source | 142,933,260Source | 133,252,585Source | 121,233,901Source | 107,215,977Source |
| Retained Earnings (Accumulated Deficit)USD | -136,952,351Source | -125,979,877Source | -145,847,123Source | -133,223,223Source | -126,641,646Source | -143,276,414Source | -131,489,872Source | -124,673,853Source | -139,719,999Source | -129,544,299Source | -121,557,074Source | -110,931,063Source |
| Stockholders' Equity Attributable to ParentUSD | 1,203,363Source | 6,908,210Source | -781,697Source | 3,389,061Source | 1,807,868Source | -340,042Source | 3,049,001Source | 3,749,112Source | 3,213,720Source | 3,708,422Source | -322,858Source | -3,714,444Source |
| Liabilities and EquityUSD | 3,179,464Source | 9,384,724Source | 2,957,273Source | 5,574,455Source | 2,795,620Source | 2,167,803Source | 4,611,874Source | 5,074,190Source | 7,452,479Source | 5,597,232Source | 2,708,085Source | 5,885,052Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,304,715Source | 2,801,784Source | 4,068,106Source | 2,513,010Source | 1,306,620Source | 2,836,815Source | 1,761,176Source | 1,636,128Source | 4,567,729Source | 2,207,197Source | 3,332,964Source | 9,464,210Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 27,315Source |
| Accounts Payable, CurrentUSD | 463,458Source | 1,967,573Source | 1,977,629Source | 1,042,832Source | 481,971Source | 1,610,186Source | 615,295Source | 981,720Source | 3,267,610Source | 1,357,079Source | 1,936,007Source | 2,943,791Source |
| Other Liabilities, NoncurrentUSD | 35Source | — | — | 1,033Source | — | — | 130,180Source | — | — | 10,096Source | 26,388Source | 310,346Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -328,649Source | -328,483Source | -329,136Source | -328,649Source | -328,483Source | -328,970Source | -328,483Source | -328,483Source | -328,970Source | -328,483Source | -328,409Source | -315,208Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 4,291Source | — | — | 5,927Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -3,729,128Source | 661,769Source | -2,570,875Source | -1,733,517Source | -3,556,415Source | -1,945,573Source | -10,176,187Source | -7,987,009Source | -10,626,275Source | -24,207,685Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 8,743Source | 16,251Source | 177,086Source | 110,723Source | 879,160Source | 1,071,843Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,663,513Source | -741,784Source | 1,815,658Source | -578,928Source | -1,234,287Source | 2,642,686Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,500,925Source | -1,707,412Source | -7,806,292Source | -7,502,700Source | -10,779,982Source | -17,887,439Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -123,643Source | — | — | 4,500Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 123,643Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -63,947Source | 1,257,826Source | 8,738,212Source | 9,881,173Source | 8,755,884Source | 8,765,905Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,564,872Source | -449,586Source | 808,277Source | 2,378,473Source | -2,024,098Source | -9,117,034Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 2,500Source | 3,200Source | 3,200Source | 1,600Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | 1,197,200Source | 326,151Source | — |
| DepreciationUSD | — | — | 0Source | 0Source | 6,533Source | 0Source | 6,533Source | 0Source | 6,533Source | 0Source | 0Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 4,500Source |
| General and Administrative ExpenseUSD | — | — | 1,279,290Source | 1,083,433Source | 1,268,952Source | 1,198,523Source | 1,176,348Source | 1,401,756Source | 4,930,701Source | 4,720,728Source | 5,361,234Source | 6,909,603Source |
| Induced Conversion of Convertible Debt ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 3,964,633Source |
| InterestExpenseNonoperatingUSD | — | — | 6,369Source | 4,063Source | 320Source | 3,160Source | 3,923Source | 3,856Source | 18,767Source | 1,290,444Source | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | -166Source | -166Source | — | — | -487Source | -74Source | -13,201Source | -35,393Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,729,128Source | 661,769Source | -2,570,709Source | -1,733,351Source | -3,556,415Source | -1,945,573Source | -10,175,700Source | -7,987,225Source | -10,626,011Source | -25,085,496Source |
| Nonoperating Income (Expense)USD | — | — | 11,967Source | 17,023Source | 5,514Source | 16,998Source | 5,815Source | 21,939Source | 64,759Source | -1,256,875Source | 91,912Source | 14,410Source |
| Operating ExpensesUSD | — | — | 4,234,199Source | 2,774,107Source | 3,740,704Source | 3,121,953Source | 4,523,229Source | 3,287,284Source | 15,307,596Source | 11,940,165Source | 12,948,707Source | 26,745,478Source |
| Other Nonoperating Income (Expense)USD | — | — | 17,338Source | 14,683Source | 5,834Source | 21,011Source | 9,738Source | 15,879Source | 73,430Source | 17,277Source | 15,420Source | 86,223Source |
| Provision for Loan, Lease, and Other LossesUSD | — | — | — | — | — | — | — | — | — | — | -150Source | -3Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 493,104Source | 3,418,853Source | 1,164,315Source | 1,371,438Source | 960,999Source | 1,319,772Source | 5,066,650Source | 5,210,031Source | 2,230,520Source | 2,523,383Source |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 493,104Source | 3,418,853Source | 1,164,315Source | 1,371,438Source | 960,999Source | 1,319,772Source | 5,066,650Source | 5,210,031Source | 2,230,520Source | 2,523,383Source |
| Operating Income (Loss)USD | — | — | -3,741,095Source | 644,746Source | -2,576,389Source | -1,750,515Source | -3,562,230Source | -1,967,512Source | -10,240,946Source | -6,730,134Source | -10,718,187Source | -24,222,095Source |
| Other Nonoperating Income (Expense)USD | — | — | 17,338Source | 14,683Source | 5,834Source | 21,011Source | 9,738Source | 15,879Source | 73,430Source | 17,277Source | 15,420Source | 86,223Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | -166Source | -166Source | — | — | -487Source | -74Source | -13,201Source | -35,393Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.29Source | 1Source | -0.2Source | -0.79Source | -0.52Source | -1.39Source | -3.98Source | -11.45Source | -4.69Source | -11.62Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.29Source | 1Source | -0.2Source | -0.79Source | -0.52Source | -1.39Source | -3.98Source | -11.45Source | -4.69Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 2,886,059Source | 659,361Source | 13,035,632Source | 2,202,299Source | 6,839,385Source | 1,401,144Source | 2,557,377Source | 697,686Source | 2,264,060Source | 2,159,189Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 2,886,059Source | 659,361Source | 13,035,632Source | 2,202,299Source | 6,839,385Source | 1,401,144Source | 2,557,377Source | 697,686Source | 2,264,060Source | — |
| Interest Expense (non-operating)USD | — | — | 6,369Source | 4,063Source | 320Source | 3,160Source | 3,923Source | 3,856Source | 18,767Source | 1,290,444Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 1,279,290Source | 1,083,433Source | 1,268,952Source | 1,198,523Source | 1,176,348Source | 1,401,756Source | 4,930,701Source | 4,720,728Source | 5,361,234Source | 6,909,603Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 353,945Source | 109,525Source |
| Interest Expense, DebtUSD | — | — | 3,208Source | 4,063Source | — | 0Source | 834Source | 909Source | 6,375Source | 8,848Source | 14,716Source | 9,909Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,729,128Source | 661,769Source | -2,570,709Source | -1,733,351Source | -3,556,415Source | -1,945,573Source | -10,175,700Source | -7,987,225Source | -10,626,011Source | -25,085,496Source |
| Nonoperating Income (Expense)USD | — | — | 11,967Source | 17,023Source | 5,514Source | 16,998Source | 5,815Source | 21,939Source | 64,759Source | -1,256,875Source | 91,912Source | 14,410Source |
| Operating ExpensesUSD | — | — | 4,234,199Source | 2,774,107Source | 3,740,704Source | 3,121,953Source | 4,523,229Source | 3,287,284Source | 15,307,596Source | 11,940,165Source | 12,948,707Source | 26,745,478Source |
| Research and Development ExpenseUSD | — | — | 2,954,909Source | 1,690,674Source | 2,471,752Source | 1,923,430Source | 3,346,881Source | 1,885,528Source | 10,376,895Source | 7,219,437Source | 7,587,473Source | 19,835,875Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 493,104Source | 3,418,853Source | 1,164,315Source | 1,371,438Source | 960,999Source | 1,319,772Source | 5,066,650Source | 5,210,031Source | 2,230,520Source | 2,523,383Source |
Offerings
Registration 333-299618
Registration 333-296499
Registration 333-294939
Filing attachments
ex107.htm · S-3 · 2026-10-23
Calculation of Filing Fee Tables S-3 Ensysce Biosciences, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maxi…
Read attachment ↗ex99-1.htm · 8-K/A · 2026-10-16
Exhibit 99.1 BUSINESS OVERVIEW Corporate Information We were originally incorporated in the State of Delaware in April 2003 as PharmacoFore, Inc. and, in January 2012, we changed our name from PharmacoFore, Inc. to Signature Therapeutics Inc. (“ Signature ”). In December 2015, Signature merged with and into Ensysce Biosciences, Inc. (“ Former Ensysce ”). In June 2021, Former Ensysce merged with and into Leisure Acquisition Corporation (“ LACQ ”). As part of the transaction, LACQ changed its n…
Read attachment ↗ex99-2.htm · 8-K/A · 2026-10-16
Exhibit 99.2 RISK FACTORS You should carefully consider the risks described below that relate to the acquisition by Ensysce Biosciences, Inc., a Delaware corporation (“we,” “us,” “our,” or the “Company”), of Cy Biopharma, Inc., a Delaware corporation (“Cy”), in accordance with the terms of an Agreement and Plan of Merger, dated August 5, 2026 (the “Merger Agreement”), by and among the Company, PHRMA Merger Sub I, Inc., PHRMA Merger Sub II, LLC, and Cy. The occurrence of any of the events or ci…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights ~ Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome ~ ~ Up to $77 million in new funding with the acquisition of Cy Biopharma ~ ~ Company to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET ~ SAN DIEGO, CA / August 13, 2026 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or the “Com…
Read attachment ↗ex99-1.htm · 8-K/A · 2026-08-06
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS) Up to $77 million in private financing consisting of $21.5 million in private placement financing at initial close plus $17.1 million of Cy Biopharma’s cash and cash equivalents from a pre-acquis…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-06
EX-99.1 9 ex99-1.htm EX-99.1 Exhibit 99.1 Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS) $21.5 million in private placement financing at initial close plus $17.1 million of Cy Biopharma’s cash and cash equivalents from a pre-acquisition convertible note financing and up to $38.6 mill…
Read attachment ↗